Calypso Biotech: Funding, Investors & Team (Oct 2026)
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
Calypso Biotech has raised $9.5M across 1 funding round on record, the most recent a Series A of $9.5M announced in Sep 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Calypso Biotech Company Profile and Key Stats
Latest funding round on record: Sep 2021.
Calypso Biotech Funding Rounds
Calypso Biotech Founders and Leadership Team
No contact details are on record for this team yet.
Calypso Biotech Funding Compared to Other Biotechnology Startups
Calypso Biotech's latest round of $9.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Calypso Biotech in Biotechnology and Plan-les-ouates
Companies Similar to Calypso Biotech
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Calypso Biotech Funding FAQs
What does Calypso Biotech do?
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
How much funding has Calypso Biotech raised?
Calypso Biotech has raised $9.5M across 1 round on record. The most recent is a Series A of $9.5M announced in Sep 2021.
When did Calypso Biotech last raise funding?
Calypso Biotech's most recent funding round on record is a Series A of $9.5M, announced in Sep 2021.
Who is the CEO of Calypso Biotech?
Alain Vicari is listed as CEO at Calypso Biotech.
Where is Calypso Biotech headquartered?
Calypso Biotech is based in Plan-les-ouates, Geneve, Switzerland.
How many employees does Calypso Biotech have?
Calypso Biotech is in the 11-50 employee band.
How does Calypso Biotech's funding compare to other Biotechnology startups?
Calypso Biotech's latest round of $9.5M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Calypso Biotech Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Calypso Biotech is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.